share_log

Processa Pharmaceuticals | DEF 14A: Definitive information statements

Processa Pharmaceuticals | DEF 14A: Definitive information statements

Processa Pharmaceuticals | DEF 14A：股東委託書決議
美股SEC公告 ·  04/30 04:37
牛牛AI助理已提取核心訊息
Processa Pharmaceuticals, Inc. (Processa) announced the filing of its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC), detailing the upcoming annual meeting of stockholders scheduled for June 28, 2024. The meeting will take place at the company's corporate office in Hanover, Maryland. Key agenda items include the election of six director nominees to serve until the 2025 Annual Meeting, approval of an amendment to increase the number of shares available under the 2019 Omnibus Incentive Plan by 500,000 shares, ratification of BD & Company, Inc. as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation. The Board of Directors is not aware of any other business to be presented for a vote. The record date for stockholder determination is set for April 29, 2024. The proxy statement also includes a cautionary note regarding forward-looking statements and details on how stockholders can vote by telephone, the Internet, or mail.
Processa Pharmaceuticals, Inc. (Processa) announced the filing of its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC), detailing the upcoming annual meeting of stockholders scheduled for June 28, 2024. The meeting will take place at the company's corporate office in Hanover, Maryland. Key agenda items include the election of six director nominees to serve until the 2025 Annual Meeting, approval of an amendment to increase the number of shares available under the 2019 Omnibus Incentive Plan by 500,000 shares, ratification of BD & Company, Inc. as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation. The Board of Directors is not aware of any other business to be presented for a vote. The record date for stockholder determination is set for April 29, 2024. The proxy statement also includes a cautionary note regarding forward-looking statements and details on how stockholders can vote by telephone, the Internet, or mail.
Processa Pharmicals, Inc.（Processa）宣佈向美國證券交易委員會（SEC）提交最終委託書（DEF 14A），詳細說明了定於2024年6月28日舉行的年度股東大會。會議將在該公司位於馬里蘭州漢諾威的公司辦公室舉行。關鍵議程項目包括選舉六名董事候選人，任期至2025年年會，批准將2019年綜合激勵計劃下可用股票數量增加50萬股的修正案，批准BD & Company, Inc.作爲截至2024年12月31日的財年獨立註冊會計師事務所，以及關於高管薪酬的諮詢投票。董事會不知道還有其他事項需要表決。股東決定的記錄日期定爲2024年4月29日。委託書還包括有關前瞻性陳述的警示說明，以及有關股東如何通過電話、互聯網或郵件進行投票的詳細信息。
Processa Pharmicals, Inc.（Processa）宣佈向美國證券交易委員會（SEC）提交最終委託書（DEF 14A），詳細說明了定於2024年6月28日舉行的年度股東大會。會議將在該公司位於馬里蘭州漢諾威的公司辦公室舉行。關鍵議程項目包括選舉六名董事候選人，任期至2025年年會，批准將2019年綜合激勵計劃下可用股票數量增加50萬股的修正案，批准BD & Company, Inc.作爲截至2024年12月31日的財年獨立註冊會計師事務所，以及關於高管薪酬的諮詢投票。董事會不知道還有其他事項需要表決。股東決定的記錄日期定爲2024年4月29日。委託書還包括有關前瞻性陳述的警示說明，以及有關股東如何通過電話、互聯網或郵件進行投票的詳細信息。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。